Patents by Inventor Michael A. Walker

Michael A. Walker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method to prevent abnormal grain growth for beta annealed Ti—6AL—4V forgings
    Patent number: 10822682
    Abstract: A method for heat-treating a titanium alloy, such as Ti-6Al-4V. The method may occur after or include a step of forging the titanium alloy such that localized, highly deformed grains are formed in the titanium alloy. Then the method may include steps of recrystallization annealing the titanium alloy by heating the titanium alloy to a temperature in a range between 30° F. to 200° F. below beta transus of the titanium alloy for 1 hour to 6 hours and then furnace cooling of the titanium alloy to 1200° F. to 1500° F. at a rate of 50° F. to 500° F. per hour. Following the recrystallization annealing, the method may include beta annealing the titanium alloy. These steps may be performed in a single heat treating cycle.
    Type: Grant
    Filed: October 4, 2018
    Date of Patent: November 3, 2020
    Assignee: Spirit AeroSystems, Inc.
    Inventors: Rahbar Nasserrafi, Gerald E. Hicks, Michael A. Walker, Craig M. Clasper
  • Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
    Patent number: 10407410
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: September 10, 2019
    Assignee: ViiV HEALTHCARE UK (NO.5) LIMITED
    Inventors: John F. Kadow, B. Narasimhulu Naidu, Manoj Patel, Michael A. Walker, Tao Wang, Zhiwei Yin, Zhongxing Zhang, Zhizhen Barbara Zheng
  • PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20190127351
    Abstract: Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS.
    Type: Application
    Filed: May 9, 2017
    Publication date: May 2, 2019
    Inventors: John F. KADOW, B. Narasimhulu NAIDU, Manoj PATEL, Michael A. WALKER, Tao WANG, Zhiwei YIN, Zhongxing ZHANG, Zhizhen Barbara ZHENG
  • METHOD TO PREVENT ABNORMAL GRAIN GROWTH FOR BETA ANNEALED TI-6AL-4V FORGINGS
    Publication number: 20190032184
    Abstract: A method for heat-treating a titanium alloy, such as Ti-6Al-4V. The method may occur after or include a step of forging the titanium alloy such that localized, highly deformed grains are formed in the titanium alloy. Then the method may include steps of recrystallization annealing the titanium alloy by heating the titanium alloy to a temperature in a range between 30° F. to 200° F. below beta transus of the titanium alloy for 1 hour to 6 hours and then furnace cooling of the titanium alloy to 1200° F. to 1500° F. at a rate of 50° F. to 500° F. per hour. Following the recrystallization annealing, the method may include beta annealing the titanium alloy. These steps may be performed in a single heat treating cycle.
    Type: Application
    Filed: October 4, 2018
    Publication date: January 31, 2019
    Applicant: Spirit AeroSystems, Inc.
    Inventors: Rahbar Nasserrafi, Gerald E. Hicks, Michael A. Walker, Craig M. Clasper
  • Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
    Patent number: 10125148
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: February 19, 2014
    Date of Patent: November 13, 2018
    Assignee: ViiV HEALTHCARE UK (NO. 5) LIMITED
    Inventors: Timothy P. Connolly, Stanley D'Andrea, John F. Kadow, David R. Langley, B. Narasimhulu Naidu, Manoj Patel, Kevin Peese, Michael A. Walker, Zhongyu Wang, Zhizhen Barbara Zheng
  • Method to prevent abnormal grain growth for beta annealed TI-6AL-4V forgings
    Patent number: 10094013
    Abstract: A method for heat-treating a titanium alloy, such as Ti-6Al-4V. The method may occur after or include a step of forging the titanium alloy such that localized, highly deformed grains are formed in the titanium alloy. Then the method may include steps of recrystallization annealing the titanium alloy by heating the titanium alloy to a temperature in a range between 30° F. to 200° F. below beta transus of the titanium alloy for 1 hour to 6 hours and then furnace cooling of the titanium alloy to 1200° F. to 1500° F. at a rate of 50° F. to 500° F. per hour. Following the recrystallization annealing, the method may include beta annealing the titanium alloy. These steps may be performed in a single heat treating cycle.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: October 9, 2018
    Assignee: Spirit AeroSystems, Inc.
    Inventors: Rahbar Nasserrafi, Gerald E. Hicks, Michael A. Walker, Craig M. Clasper
  • METHOD TO PREVENT ABNORMAL GRAIN GROWTH FOR BETA ANNEALED TI-6AL-4V FORGINGS
    Publication number: 20170175241
    Abstract: A method for heat-treating a titanium alloy, such as Ti-6Al-4V. The method may occur after or include a step of forging the titanium alloy such that localized, highly deformed grains are formed in the titanium alloy. Then the method may include steps of recrystallization annealing the titanium alloy by heating the titanium alloy to a temperature in a range between 30° F. to 200° F. below beta transus of the titanium alloy for 1 hour to 6 hours and then furnace cooling of the titanium alloy to 1200° F. to 1500° F. at a rate of 50° F. to 500° F. per hour. Following the recrystallization annealing, the method may include beta annealing the titanium alloy. These steps may be performed in a single heat treating cycle.
    Type: Application
    Filed: December 17, 2015
    Publication date: June 22, 2017
    Applicant: Spirit AeroSystems, Inc.
    Inventors: Rahbar Nasserrafi, Gerald E. Hicks, Michael A. Walker, Craig M. Clasper
  • PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    Publication number: 20170008909
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: February 19, 2014
    Publication date: January 12, 2017
    Inventors: Timothy P. CONNOLLY, Stanley D'ANDREA, John F. KADOW, David R. LANGLEY, B. Narasimhulu NAIDU, Manoj PATEL, Kevin PEESE, Michael A. WALKER, Zhongyu WANG, Zhizhen Barbara ZHENG
  • Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
    Patent number: 9273067
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for making and using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: March 1, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Michael A. Walker, Margaret E. Sorenson, Manoj Patel, Zhizhen Barbara Zheng, John F. Kadow, Bin Zheng, Martin D. Eastgate, Ke Chen, Francisco Gonzalez-Bobes
  • Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication
    Publication number: 20150232481
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for making and using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: February 11, 2015
    Publication date: August 20, 2015
    Inventors: B. Narasimhulu Naidu, Michael A. Walker, Margaret E. Sorenson, Manoj Patel, Zhizhen Barbara Zheng, John F. Kadow, Bin Zheng, Martin D. Eastgate, Ke Chen, Francisco Gonzalez-Bobes
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 8906929
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: August 5, 2013
    Date of Patent: December 9, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Manoj Patel, Stanley D'Andrea, Zhizhen Barbara Zheng, Timothy P. Connolly, David R. Langley, Kevin Peese, Zhongyu Wang, Michael A. Walker, John F. Kadow
  • HIV integrase inhibitors
    Patent number: 8846659
    Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: September 30, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kevin Peese, B. Narasimhulu Naidu, Manoj Patel, Chen Li, Michael A. Walker
  • HIV integrase inhibitors
    Patent number: 8835411
    Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: September 16, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yasutsuga Ueda, Timothy P. Connolly, Barry L. Johnson, Chen Li, B. Narasimhulu Naidu, Manoj Patel, Kevin Peese, Margaret E. Sorenson, Michael A. Walker, Michael S. Bowsher, Rongti Li
  • Inhibitors of Human Immunodeficiency Virus Replication
    Publication number: 20140051692
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Application
    Filed: August 5, 2013
    Publication date: February 20, 2014
    Inventors: B. Narasimhulu Naidu, Manoj Patel, Stanley D'Andrea, Zhizhen Barbara Zheng, Timothy P. Connolly, David R. Langley, Kevin Peese, Zhongyu Wang, Michael A. Walker, John F. Kadow
  • Inhibitors of human immunodeficiency virus replication
    Patent number: 8629276
    Abstract: The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: February 13, 2013
    Date of Patent: January 14, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael A. Walker, Margaret E. Sorenson, B. Narasimhulu Naidu, Kevin Peese, Barry L. Johnson, Manoj Patel
  • HIV integrase inhibitors
    Patent number: 8383639
    Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: February 26, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Kevin Peese, Ira B. Dicker, Chen Li, Manoj Patel, Nicholas A. Meanwell, Michael A. Walker
  • HIV Integrase Inhibitors
    Publication number: 20120309698
    Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Application
    Filed: December 6, 2011
    Publication date: December 6, 2012
    Inventors: Yasutsugu Ueda, Timothy P. Connolly, Barry L. Johnson, Chen Li, B. Narasimhulu Naidu, Manoj Patel, Kevin Peese, Margaret E. Sorenson, Michael A. Walker, Michael S. Bowsher, Rongti Li
  • HIV Integrase Inhibitors
    Publication number: 20120309745
    Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Application
    Filed: December 7, 2011
    Publication date: December 6, 2012
    Inventors: Kevin Peese, B. Narasimhulu Naidu, Manoj Patel, Chen Li, Michael A. Walker
  • HIV integrase inhibitors
    Patent number: 8129398
    Abstract: The disclosure generally relates to the novel compounds of formula I, including their salts, which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: March 6, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Francis Beaulieu, Carl Ouellet, B. Narasimhulu Naidu, Manoj Patel, Yasutsugu Ueda, Timothy P. Connolly, Jonathan R. Weiss, Michael A. Walker, Nicholas A. Meanwell, Kevin M. Peese, Margaret E. Sorenson, Chen Li
  • HIV integrase inhibitors
    Patent number: 8039458
    Abstract: The invention encompasses a series bicyclic pyrimidinone compounds of Formula I which inhibit HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.
    Type: Grant
    Filed: October 31, 2006
    Date of Patent: October 18, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: B. Narasimhulu Naidu, Yasutsugu Ueda, John D. Matiskella, Michael A. Walker, Jacques Banville, Francis Beaulieu, Carl Ouellet, Serge Plamondon